Investing requires patience and a long time horizon to generate sizable profits. It’s no secret that the most successful investors are people such as Warren Buffett, who are infinitely patient and hold stocks in their portfolios for decades. Buffett famously said, “The stock market is a device to transfer money from the ‘impatient’ to the ‘patient.'” While patience is certainly a virtue when it comes to investing, it also helps to identify strong companies when they first come to market and take a position early in their life as a publicly traded concern. This is when companies are experiencing rapid growth and have a long runway ahead of them. Spotting winning overlooked growth stocks, taking a position early and holding on for the long-term is a recipe for success as an investor. Here are three overlooked growth stocks for patient investors. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cava Group (CAVA) Cava Group is a restaurant chain founded in 2006 in Rockville, Maryland, by Ted Xenohristos, Chef Dimitri Moshovitis and Ike Grigoropoulos. Source: Nicole Glass Photography / Shutterstock.com Mediterranean restaurant chain Cava Group (NYSE:CAVA) has only been publicly traded for a year but has enjoyed an incredible run. Since its initial public offering (IPO) in June 2023, CAVA stock has increased 150%. The company is also profitable and has reported financial results that consistently top Wall Street forecasts. This makes Cava Group one of the most successful IPOs of the last five years. The company’s strong financial results are driven by huge growth, which continues to create an enormous market opportunity. For this year’s first quarter, Cava reported EPS of 13 cents, more than double the 5 cents expected among analysts. Revenue in the quarter totaled $259 million, ahead of Wall Street expectations for $246 million. Sales were up 30% from a year earlier. Much of the growth came from Cava’s rapid expansion as the company opened 14 new restaurant locations during the quarter, bringing its national count to 323 outlets. According to management, Cava is now forecasting full-year earnings of $100 million to $105 million. That’s an increase from an earlier forecast of $86 million to $92 million. Many analysts compare Cava to Chipotle Mexican Grill (NYSE:CMG). Arm Holdings (ARM) ARM company logo on the paper document and large microchips placed around. Illustrative for electronic chip manufacturer. Source: Ascannio / Shutterstock.com If there’s one stock that has had an even more impressive market debut than Cava Group, it’s British microchip and semiconductor concern Arm Holdings (NASDAQ:ARM). Since going public in September 2023, ARM stock has risen 200%. And more gains appear likely. The growth trajectory of ARM stock has been so strong that the company was just added to the Nasdaq 100 index, replacing satellite radio provider Sirius XM (NASDAQ:SIRI). Arm Holdings was added to the Nasdaq 100 due to its explosive market capitalization approaching $200 billion. Like Cava, Arm is already profitable and growing at a brisk clip. The company most recently reported fiscal fourth-quarter revenue of $928 million, a 47% increase from a year ago. Demand for artificial intelligence (AI) chips is powering its sales growth. In terms of profit, Arm earned 36 cents per share, beating forecasts of 31 cents a share. Viking Therapeutics (VKTX) Light blue pills on white background. Pharmaceutical industry, medical treatment, presciption drugs concept. Digital 3D render., biotech stocks, big pharma. EVAX stock Source: Hernan E. Schmidt / Shutterstock.com Worried that you’ve missed out on the boom in weight loss drugs with pharmaceutical giants Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). Not to worry. You can still gain exposure to the weight loss drug trade with Viking Therapeutics (NASDAQ:VKTX), the newest and potentially most explosive entrant in the weight loss drug market. VKTX stock is up 180% this year on reports that its weight loss candidate has shown extremely good results. However, there’s another reason to consider Viking Therapeutics stock. Rumors that a larger pharmaceutical company such as Pfizer (NYSE:PFE) might acquire Viking Therapeutics to gain access to its weight loss drugs acting as a catalyst for the stock too. Whether Viking remains independent and brings its weight loss drug to market or is acquired by a larger company at a premium price, investors don’t look likely to lose with VKTX stock. On the date of publication, Joel Baglole held a long position in LLY. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article. Joel Baglole has been a business journalist for 20 years. He spent five years as a staff reporter at The Wall Street Journal, and has also written for The Washington Post and Toronto Star newspapers, as well as financial websites such as The Motley Fool and Investopedia. More From InvestorPlace Legendary Investor Predicts: “Forget A.I. THIS Technology Is the Future” The post 3 Overlooked Giants-in-the-Making for Patient Investors appeared first on InvestorPlace.
3 Overlooked Giants-in-the-Making for Patient Investors
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...